Fluocinolone acetonide intravitreal sustained release device ? a new addition to the armamentarium of uveitic management
Open Access
- 1 March 2007
- journal article
- review article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 2 (1) , 55-64
Abstract
Uveitis is a potentially sight-threatening inflammatory eye disease caused by multiple infectious and non-infectious etiologies for which the standard of care involves corticosteroids or various immunomodulary therapy (IMT) drugs. These available treatments, although effective, may cause significant morbidity and sometimes mortality in uveitis patients due to their toxic side-effects and the necessity of long-term therapy to prevent recurrences. In order to avoid the systemic toxicity ofcorticosteroids and IMT or the repeated injections of local steroids necessary to control ocular inflammation, and to prevent development of cumulative damage resulting from recurrent episodes of inflammation, researchers have developed a number of local corticosteroid sustained-release devices that can be implanted directly into the vitreous of the eye, at the site of the inflammatory disease. Preliminary studies of such a device, the fluocinolone acetonide (Retisert) implant, have shown significant reductions in the number of inflammatory episodes and decreased reliance on systemic corticosteroids or other IMT. This review explores the current research evaluating the fluocinolone sustained-release intravitreal implant in the treatment of posterior uveitis and the implications for its future use on a wider scale.Keywords
This publication has 17 references indexed in Scilit:
- Fluocinolone Acetonide Implant (Retisert) for Noninfectious Posterior UveitisOphthalmology, 2006
- Ocular Pharmacokinetics of Fluocinolone Acetonide After Retisert™ Intravitreal Implantation in Rabbits Over a 1-Year PeriodJournal of Ocular Pharmacology and Therapeutics, 2004
- COMPLICATIONS OF GANCICLOVIR IMPLANT SURGERY IN PATIENTS WITH CYTOMEGALOVIRUS RETINITISRetina, 2004
- Ocular complications of topical, peri-ocular, and systemic corticosteroidsCurrent Opinion in Ophthalmology, 2000
- Fluocinolone acetonide sustained drug delivery device to treat severe uveitisOphthalmology, 2000
- Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device2000
- DEXAMETHASONE SUSTAINED DRUG DELIVERY IMPLANT FOR THE TREATMENT OF SEVERE UVEITISRetina, 2000
- Treatment Strategies in Patients With Posterior UveitisInternational Ophthalmology Clinics, 2000
- Treatment of Cytomegalovirus Retinitis with a Sustained-Release Ganciclovir ImplantNew England Journal of Medicine, 1997
- Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis.1995